Researchers showed that treatment with the antiandrogen enzalutamide—a well-tolerated drug widely used in advanced prostate cancer—reducesd transmembrane serine protease 2 (TMPRSS2) levels in human lung cells and in mouse lung.
[Nature Communications]
7753456
{7753456:U7UTCSD2}
apa
50
1
164123
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
